Company Overview and News

 
Fast Fringe presents 15 ways to take a chance at the Edmonton Fringe Festival

2018-08-18 cbc.ca
Although the festival is the biggest and one of the oldest, the artistic director still believes the festival is about taking chances.
CAS

 
New Harry Potter LEGO Hogwarts is the Second Largest Set Ever /Film

2018-07-30 slashfilm
Back in February, we told you that a bunch of new Harry Potter LEGO sets were on the way. Several of the new sets are already on sale, but LEGO just revealed what will undoubtedly be the crown jewel of their new Harry Potter LEGO sets.
CAS

 
Die Hard at 30: The Cast and Crew Reflect On Making An Action Classic – /Film

2018-07-13 slashfilm
(This week marks the 30th anniversary of Die Hard, arguably the greatest action movie of all time. To celebrate, /Film is exploring the film from every angle with a series of articles. Today: the cast and crew look back on the making of an action classic.)
CAS

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to EPA:CAS / CAST on message board site Silicon Investor.

Biotech for less than cash value Biotech for less than cash value Biotech for less than cash value Casinos/Gambling and Favorite Destination Spots Casinos/Gambling and Favorite Destination Spots Casinos/Gambling and Favorite Destination Spots
Low Price/Cash Ratio Value Stocks Low Price/Cash Ratio Value Stocks Low Price/Cash Ratio Value Stocks The Case for Nuclear Energy The Case for Nuclear Energy The Case for Nuclear Energy
TNA.V - Evergreen Gaming Corporation (Casino u0026 Restaurant) TNA.V - Evergreen Gaming Corporation (Casino u0026 Restaurant) TNA.V - Evergreen Gaming Corporation (Casino u0026 Restaurant) The Castle The Castle The Castle
(CTX.TO)MC $9 M / Cash $9 M / Low Float / 5 Marketed Product (CTX.TO)MC $9 M / Cash $9 M / Low Float / 5 Marketed Product (CTX.TO)MC $9 M / Cash $9 M / Low Float / 5 Marketed Product AYTU (MC $16 M) (Cash $11.8 M) 4 Marketed Products +Big Drug AYTU (MC $16 M) (Cash $11.8 M) 4 Marketed Products +Big Drug AYTU (MC $16 M) (Cash $11.8 M) 4 Marketed Products +Big Drug
SNOA (MC $23 M) (Cash $13 M) Lots of Marketed Products SNOA (MC $23 M) (Cash $13 M) Lots of Marketed Products SNOA (MC $23 M) (Cash $13 M) Lots of Marketed Products KTOV ($16 M) (Cash $17 M) US-NDA Submission this Quarter KTOV ($16 M) (Cash $17 M) US-NDA Submission this Quarter KTOV ($16 M) (Cash $17 M) US-NDA Submission this Quarter